Isracann Biosciences to Acquire Praesidio Health
February 23, 2022
Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.
- Buyers
- Isracann Biosciences Inc.
- Targets
- Praesidio Health Inc.
- Industry
- Biotechnology
- Location
- Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Praesidian Capital Acquires Undisclosed Genetics Business
September 18, 2019
Healthcare Services
Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.
-
ICON plc Acquires PRA Health Sciences
February 24, 2021
Healthcare Services
ICON plc agreed to acquire PRA Health Sciences in a cash-and-stock transaction valued at approximately $12 billion, with PRA shareholders receiving $80 in cash and 0.4125 shares of ICON. The deal creates a combined company headquartered in Dublin, Ireland (retaining the ICON name) with expanded clinical trial scale, healthcare intelligence capabilities and approximately 38,000 employees, enabling broader decentralized and hybrid trial solutions.
-
Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.
February 11, 2020
Pharmaceuticals
Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.
-
DeliverHealth Acquires PresidioHealth
March 21, 2022
Healthcare Services
DeliverHealth, a Madison-based provider of software and technology-enabled services for hospitals and health systems, has acquired San Francisco–based PresidioHealth. The acquisition integrates PresidioHealth’s SaaS coding and clinical intelligence capabilities into DeliverHealth’s platform to improve coding quality, documentation, and accelerate reimbursement for provider customers.
-
MediPharm Labs Corp. Acquires VIVO Cannabis Inc.
April 1, 2023
Pharmaceuticals
Effective April 1, 2023, MediPharm Labs Corp. completed an all-equity arrangement to acquire all outstanding shares of VIVO Cannabis Inc., making VIVO a wholly-owned subsidiary. Under the arrangement, former VIVO shareholders received 0.2910 MediPharm common shares per VIVO share and MediPharm issued approximately 107,930,964 shares as consideration; VIVO shares are expected to be delisted from the Toronto Stock Exchange.
-
Affiliates of Funds Advised by BC Partners Acquire Presidio, Inc.
December 19, 2019
IT Services
Affiliates of funds advised by BC Partners completed an all-cash acquisition of Presidio, Inc. for approximately $2.2 billion (including net debt), taking the company private and resulting in the delisting of Presidio’s common stock. BC Partners said the transaction will support Presidio’s growth initiatives and strategic investments to expand its digital infrastructure, cloud and security capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.